Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate Cancer

Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

DOI

  1. Active Surveillance Versus Radical Prostatectomy in Favorable-risk Localized Prostate Cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Quality of Life in Long-Term Testicular Cancer Survivors With Compensated Leydig Cell Dysfunction

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Preorchiectomy Leydig Cell Dysfunction in Patients With Testicular Cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Long-term neurotoxicity and quality of life in testicular cancer survivors-a nationwide cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Small RNAs in Seminal Plasma as Novel Biomarkers for Germ Cell Tumors

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Late adverse effects and quality of life in survivors of testicular germ cell tumour

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  4. Adverse health behaviours in long-term testicular cancer survivors: a Danish nationwide study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Daniel Heinrich
  • Jasmin Bektic
  • Andries M Bergman
  • Orazio Caffo
  • Richard Cathomas
  • Kim N Chi
  • Gedske Daugaard
  • Daniel Keizman
  • Jon Kindblom
  • Gero Kramer
  • David Olmos
  • Aurelius Omlin
  • Srikala S Sridhar
  • Marcello Tucci
  • Inge van Oort
  • Sten Nilsson
Vis graf over relationer

Radium-223 dichloride (radium-223) was approved for the treatment of patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases in the United States and Europe in 2013. This followed a reported overall survival benefit for patients treated with radium-223 and best standard of care (BSoC) when compared with placebo and BSoC in the ALpharadin in SYMptomatic Prostate CAncer (ALSYMPCA) trial. At that time, docetaxel was the standard first-line choice for patients with metastatic CRPC (mCRPC). Since then, the treatment landscape has changed dramatically with new hormonal agents (abiraterone and enzalutamide) considered to be the first-line choice for many patients. The optimal patient profile for radium-223 in the modern setting, and its best use either in sequence or in combination with other approved agents are unclear, with few definitive guidelines available. This article reports on the views of a group of urologists and medical oncologists experienced in treating patients with mCRPC with radium-223 in routine clinical practice. The aim is to provide an overview of the current use of radium-223 in the treatment of patients with mCRPC, and to discuss best practices for patient selection and on-treatment monitoring. Where agreement was reached, guidance on the optimal use of radium-223 is provided.

OriginalsprogEngelsk
TidsskriftClinical Genitourinary Cancer
Vol/bind16
Udgave nummer1
Sider (fra-til)e223-e231
ISSN1938-0682
DOI
StatusUdgivet - 2018

ID: 55865862